loader image

Millions of people around the world are suffering from a number of neurodegenerative disorders.

And the number is increasing in an alarming rate.

Neurodegenerative disease is not a single disease, but a complex syndrome with multi-factorial causes.

Our platform will screen and identify each patient with their specific traits.

Each patient should be studied and evaluated in order for them to receive personalized and tailor-made medicine for better and efficient treatment.

Our platform is also developing a multitude of drug candidates with an effective and patient-friendly drug delivery model such as intranasal administration.

Our mission is to make available effective disease-modifying drugs for the patients with highly unmet neurodegenerative disorders.


Our Science

  • Excellent Animal Proof of Concept
  • Multiple mechanism of actions (MOAs)
  • Precision Medicine
  • Patient-focused Model


  • Our extraordinary multiple assets, unlike others
  • 8 drug candidates
  • Combo drugs

Contact Us

Your opinion is important for us to understand and address these challenging neurodegenerative diseases. Please drop us a message if you are interested in learning more of our science and drug development program.

Press Releases


Forest Hills Lab Expands Pipeline and Readies for Clinical Development

Read More


FHL Announces Phase 2 Clinical Trial for Parkinson’s Drug, Korean Medical Device Company Acquisition and Saudi JV

Read More


Forest Hills Lab將向美國食品藥品監督管理局提交研究性新藥申請

Read More

PR Newswire

Forest Hills Lab將向美國食品藥品監督管理局提交研究性新藥申請

Read More

Parkinson’s News Today

Forest Hills Lab Asking to Open Phase 2 Trial of FHL-301 in Parkinson’s

Read More


3 Notable Neuroscience Discoveries in 2021

Read More

Yahoo Finance

Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson’s disease with the US FDA

Read More